Dark

Check out our API

ATNX
Athenex, Inc. Common Stock
stock NASDAQ

Inactive

May 24, 2023

0.2031USD-23.387%(-0.0620)1,880,202

Pre-market

0.00USD-100.000%(-0.27)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 12, 2022

08:32AM EST Athenex Reports Deal For ImmunityBio To Assume Leasehold Interest In Manufacturing Facility In Dunkirk, New York, Certain Related Assets For ~$38M Benzinga

08:30AM EST Athenex Announces Agreement with ImmunityBio Regarding Dunkirk GlobeNewswire Inc

Dec 13, 2021

07:05AM EST Athenex To Host A KOL Webinar Today On CAR-NKT Cell Approach To Cancer And Latest Data At The 63rd ASH Annual Meeting Benzinga

07:00AM EST The Company will host a virtual Key Opinion Leader event today at 9:00 a.m. ET to discuss its CAR-NKT cell therapy platform GlobeNewswire Inc

Nov 30, 2021

08:00AM EST Presentations Will Include a Review of ANCHOR Study Data on KUR-502 from ASH Annual Meeting GlobeNewswire Inc

Nov 29, 2021

08:40AM EST Athenex, Inc. (ATNX) said its Marketing Authorization Application for oral Paclitaxel for the treatment of advanced breast cancer has been validated by the United Kingdom's Medicines and Healthcare products Regulatory Agency for review. A single pivotal phase III study of oral Paclitaxel was the basis of the Marketing Authorization Application. RTTNews

08:21AM EST Athenex Announces UK MHRA Validation Of MAA For Oral Paclitaxel And Encequidar For Review RTTNews

08:11AM EST Athenex Announces UK MHRA Validation Of The Marketing Authorization Application For Oral Paclitaxel And Encequidar For Review Benzinga

08:00AM EST Athenex Announces UK MHRA Validation of the Marketing GlobeNewswire Inc

Nov 22, 2021

08:05AM EST Athenex To Present Subgroup Analysis From Phase 3 Study Of Oral Paclitaxel Plus Encequidar In Metastatic Breast Cancer At SABCS 2021 Benzinga

08:00AM EST Analysis of safety data demonstrated that patients with elevated liver tests were at increased risk of neutropenia related toxicities GlobeNewswire Inc

Nov 18, 2021

08:00AM EST Athenex to Present at the Evercore ISI 4th Annual HealthCONx GlobeNewswire Inc

Nov 9, 2021

11:44AM EST Athenex Announces Exclusive License Agreement With National Cancer Institute To Utilize T Cell Receptors Targeting Mutated p53, KRAS, And EGFR For The Development Of Autologous And Allogeneic Cell Therapies Benzinga

08:00AM EST Athenex Announces Exclusive License Agreement with National Cancer GlobeNewswire Inc

Nov 4, 2021

07:13AM EDT Athenex Q3 EPS $(0.33) Beats $(0.37) Estimate, Sales $32.30M Beat $24.02M Estimate Benzinga

07:00AM EDT Held FDA Type A Meeting for oral paclitaxel in metastatic breast cancer GlobeNewswire Inc

05:00AM EDT Earnings Scheduled For November 4, 2021 Benzinga

Nov 3, 2021

11:04AM EDT Earnings Preview For Athenex Benzinga

Oct 22, 2021

04:05PM EDT Athenex to Provide Corporate and Financial Update for the Third GlobeNewswire Inc

Oct 18, 2021

08:23AM EDT Athenex And Center For Cell And Gene Therapy Announce Allowance Of First US Patent Claims Around CAR-NKT Cell Therapy Benzinga

08:15AM EDT Patent includes a pharmaceutical composition claim comprising a plurality of genetically modified CD62L-positive human NKT cells comprising at least one chimeric antigen receptor (CAR) GlobeNewswire Inc

Oct 12, 2021

08:13AM EDT The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology Benzinga

06:59AM EDT RBC Capital Maintains Outperform on Athenex, Lowers Price Target to $5 Benzinga

Oct 11, 2021

08:02AM EDT Athenex Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel + Encequidar In Metastatic Breast Cancer Benzinga

08:00AM EDT Athenex Provides Update from FDA Type A Meeting Regarding Oral GlobeNewswire Inc

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 27, 2021

08:14AM EDT Athenex Announces Phased European Launch Of Klisyri For Treatment Of Actinic Keratosis Benzinga

08:00AM EDT Klisyri has been approved for the treatment of actinic keratosis by the UK Medicines and Healthcare products Regulatory Agency and will initially be available for prescription in the UK and Germany GlobeNewswire Inc

Sep 16, 2021

02:30AM EDT Athenex Presents Data from Oral Paclitaxel + Pembrolizumab Phase 1 GlobeNewswire Inc

Sep 15, 2021

08:00AM EDT Athenex to Present at the Oppenheimer 2021 Fall Healthcare Life GlobeNewswire Inc

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 6, 2021

09:53AM EDT RBC Capital Maintains Outperform on Athenex, Lowers Price Target to $8 Benzinga

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

05:46AM EDT SVB Leerink Maintains Market Perform on Athenex, Lowers Price Target to $4 Benzinga

Aug 5, 2021

07:00AM EDT Athenex Provides Second Quarter 2021 Corporate and Financial Update GlobeNewswire Inc

04:08AM EDT Earnings Scheduled For August 5, 2021 Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 26, 2021

10:02AM EDT Athenex Inks Commercialization Pacts For Tirbanibulin In Australia, New Zealand Benzinga

07:02AM EDT Athenex Announces Licensing Agreements With Seqirus Pty And AVIR Pharma For Tirbanibulin; Seqirus To Have Exclusive License In Australia And New Zealand, AVIR To Have Exclusive License In Canada Benzinga

07:00AM EDT Athenex Announces Additional Licensing Agreements for Tirbanibulin GlobeNewswire Inc

Jul 22, 2021

08:48AM EDT Athenex to Provide Corporate and Financial Update for the Second GlobeNewswire Inc

Jul 19, 2021

10:53AM EDT Athenex Reports European Commission Approval Of Klisyri For Topical Treatment Of Actinic Keratosis Benzinga

10:52AM EDT Athenex Announces European Commission Approval of GlobeNewswire Inc

Jul 7, 2021

07:50AM EDT 'Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors' - ClinicalTrials.gov Benzinga

Jul 6, 2021

09:20AM EDT Athenex Issues Update On Oral Paclitaxel Application In Metastatic Breast Cancer Benzinga

07:11AM EDT Athenex Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar For Metastatic Breast Cancer RTTNews

07:01AM EDT Athenex Provides Update From FDA Type A Meeting Regarding Oral Paclitaxel Plus Encequidar For The Treatment Of Metastatic Breast Cancer Benzinga

07:00AM EDT Athenex Provides Update from FDA Type A Meeting Regarding Oral GlobeNewswire Inc

Jun 7, 2021

10:59AM EDT Athenex Shares Move Higher; Co Publishes Trial Titled 'Evaluate TCRT-ESO-A2 Autologous T Cells Expressing TCR Specific for NY-ESO-1 in Subjects With Advanced Solid Tumors' To ClinicalTrials.Gov Benzinga

Jun 4, 2021

09:09AM EDT Athenex Highlights Data For 2 Poster Presentations At American Society Of Clinical Oncology Benzinga

09:05AM EDT -- Data from oral docetaxel phase I pharmacokinetic study shows oral administration can achieve exposure comparable to IV docetaxel -- Post-hoc subgroup efficacy analysis based on updated tumor subtypes in the oral paclitaxel phase III study demonstrated an improved response rate with oral paclitaxel plus encequidar across tumor subgroups GlobeNewswire Inc

May 21, 2021

09:22AM EDT Athenex Reports Positive CHMP Opinion For Klisyri For Treatment Of Actinic Keratosis Of The Face, Scalp Benzinga

09:22AM EDT Athenex Announces Klisyri (tirbanibulin) Receives GlobeNewswire Inc

May 17, 2021

07:00AM EDT -- Data presented by investigators from the Texas Childrens Cancer Center -- One PR, one CR and four SDs out of 11 patients enrolled -- GD2 CAR NKT cells were well tolerated with no dose limiting toxicities -- CAR-NKT AUC normalized to disease burden (AUC/Curie score) was associated with response to therapy. GlobeNewswire Inc

May 14, 2021

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 6, 2021

07:49AM EDT The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom Benzinga

07:36AM EDT Athenex: Q1 Earnings Insights Benzinga

07:29AM EDT Athenex Q1 EPS $(0.27) Beats $(0.40) Estimate, Sales $41.02M Beat $24.54M Estimate Benzinga

07:00AM EDT Plan to Request Type A Meeting with the FDA for Oral Paclitaxel by the End of May GlobeNewswire Inc

04:17AM EDT Earnings Scheduled For May 6, 2021 Benzinga

May 5, 2021

12:17PM EDT Mid-Day Market Update: Crude Oil Rises 1%; Esperion Therapeutics Shares Drop Following Q1 Results Benzinga

10:26AM EDT Mid-Morning Market Update: Markets Mostly Lower; General Motors Profit Beats Estimates Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

07:00AM EDT Athenex Shares Gain After Acquiring Kuur Therapeutics For $70M Cash, $115M Milestone Payments Benzinga

May 4, 2021

05:22PM EDT Athenex To Acquire Kuur Therapeutics For Total Potential Consideration Of $185M, Comprising Of $70M Upfront Payment And $115M In Development Milestones Benzinga

May 1, 2021

05:37PM EDT Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 27, 2021

04:05PM EDT Athenex to Provide Corporate and Financial Update for the First GlobeNewswire Inc

Apr 26, 2021

11:46AM EDT Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 24, 2021

01:14AM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

Apr 19, 2021

01:21PM EDT Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Apr 14, 2021

11:07PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with GlobeNewswire Inc

07:51AM EDT The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead Benzinga

Apr 12, 2021

07:14PM EDT Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Mar 23, 2021

10:28PM EDT Pomerantz Law Firm Announces the Filing of a Class Action against Athenex, PR Newswire

01:46PM EDT Gainey McKenna & Egleston Announces A Class Action Lawsuit Has GlobeNewswire Inc

Mar 22, 2021

05:09PM EDT Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Mar 9, 2021

05:42PM EST HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Athenex (ATNX) Investors PR Newswire

Mar 8, 2021

06:57PM EST Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. GlobeNewswire Inc

Mar 4, 2021

08:12AM EST The Daily Biotech Pulse: FDA Nod For Pfizer, Kiniksa Rises On Commercialization Pact With Regeneron, Bio-Techne To Buy Diagnostic Company Benzinga

Mar 3, 2021

05:03PM EST Hagens Berman urges Athenex, Inc. (NASDAQ: ATNX) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims. GlobeNewswire Inc

Mar 2, 2021

09:56PM EST with Losses to Contact Its Attorneys, ATNX Reports FDA Complete Response Letter PR Newswire

10:49AM EST Oppenheimer Downgrades Athenex to Perform Benzinga

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021 Benzinga

08:01AM EST The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data Benzinga

08:00AM EST 10 Biggest Price Target Changes For Tuesday Benzinga

06:32AM EST Truist Securities Downgrades Athenex to Hold, Lowers Price Target to $6 Benzinga

06:19AM EST JP Morgan Downgrades Athenex to Neutral, Lowers Price Target to $7 Benzinga

05:20AM EST SVB Leerink Downgrades Athenex to Market Perform, Lowers Price Target to $5 Benzinga

Mar 1, 2021

08:29PM EST Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Athenex, Inc. (Athenex or the Company) (NASDAQ: ATNX) to determine whether the Company engaged in securities fraud or other unlawful business practices. GlobeNewswire Inc

02:37PM EST Mid-Afternoon Market Update: Crud Oil Down Over 1%; Morphic Shares Spike Higher Benzinga

12:17PM EST Mid-Day Market Update: Dow Jumps Over 600 Points; CorMedix Shares Plummet Benzinga

10:13AM EST Mid-Morning Market Update: Markets Open Higher; Johnson & Johnson Receives FDA Approval For COVID-19 Vaccine Benzinga

09:57AM EST Athenex Inc.'s (ATNX) shares more than halved in value on Monday morning after the biopharmaceutical company received a completed response letter from FDA regarding its oral paclitaxel plus encequidar for the treatment of metastatic breast cancer. RTTNews

07:39AM EST Athenex: Q4 Earnings Insights Benzinga

07:29AM EST Athenex Shares Are Trading Lower After FDA Rejected Oral Paclitaxel Plus Encequidar Application In Breast Cancer Benzinga

07:22AM EST Athenex Q4 Loss Per Share $0.53 Vs Loss $0.28 Last Year RTTNews

07:21AM EST Athenex Gets FDA Complete Response Letter For Oral Paclitaxel Plus Encequidar For Metastatic Breast Cancer RTTNews

07:17AM EST Athenex Q4 EPS $(0.53) Misses $(0.44) Estimate, Sales $21.80M Beat $20.71M Estimate Benzinga

07:05AM EST Athenex Provides Fourth Quarter and Full Year 2020 Corporate and GlobeNewswire Inc

07:02AM EST Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer Benzinga

07:00AM EST Athenex Receives FDA Complete Response Letter for Oral Paclitaxel GlobeNewswire Inc

03:51AM EST Earnings Scheduled For March 1, 2021 Benzinga

Feb 27, 2021

09:04PM EST The Week Ahead In Biotech (Feb. 28-March 6): KemPharm, Gilead FDA Decisions and More Earnings Benzinga

Feb 26, 2021

10:17AM EST Athenex's Earnings Outlook Benzinga

Feb 22, 2021

07:00AM EST Athenex to Provide a Corporate and Financial Update for the Fourth GlobeNewswire Inc

Feb 18, 2021

09:24AM EST Athenex Launches Klisyri In US For Actinic Keratosis; Expands Tirbanibulin Distribution Pact For Additional Territories Benzinga

08:00AM EST Almirall U.S. Launches Klisyri, A New, Innovative Topical Treatment For Actinic Keratosis RTTNews

07:55AM EST Almirall U.S. Launches Klisyri(r) (tirbanibulin), a New, Innovative Topical PR Newswire

07:55AM EST Athenex Highlighs US Launch Of Klisyri, Licensing Of Added Territories For Tirbanibulin Benzinga

07:55AM EST Athenex Announces U.S. Launch of Klisyri and Licensing GlobeNewswire Inc

Feb 11, 2021

07:01AM EST Almirall announces New England Journal of Medicine publication of Phase III PR Newswire

07:00AM EST Athenex Announces New England Journal of Medicine Publication of GlobeNewswire Inc

Jan 31, 2021

05:22AM EST Attention Biotech Investors: Mark Your Calendar For February PDUFA Dates Benzinga

Jan 25, 2021

04:08PM EST Athenex CEO Dr. Johnson Lau Recuperating From COVID At Home Benzinga

04:05PM EST CEO Dr. Johnson Lau Recuperating from COVID at Home GlobeNewswire Inc

Jan 8, 2021

04:10PM EST Athenex In Press Release Says CEO Johnson Contracted COVID-19; Shares Up After Hours Benzinga

04:05PM EST CEO Dr. Johnson Lau Contracts COVID-19 GlobeNewswire Inc

Jan 5, 2021

04:30PM EST Athenex to Present at the 39th Annual J.P. Morgan Healthcare GlobeNewswire Inc

Dec 15, 2020

09:55AM EST Athenex shares were trading higher after the company announced that the FDA approved its Klisyri topical treatment for actinic keratosis. Benzinga

07:11AM EST Almirall :FDA Oks Klisyri, New Topical Treatment For Actinic Keratosis RTTNews

07:02AM EST Athenex Announces FDA Approval Of Klisyri Topical Treatment For Actinic Keratosis Benzinga

07:01AM EST Almirall announces FDA approval of Klisyri(r) (tirbanibulin), a new innovative PR Newswire

07:00AM EST -- Klisyri is the first FDA approved proprietary product for Athenex -- First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course -- Klisyri will be manufactured by Athenex -- Almirall will launch Klisyri in the U.S. in first quarter 2021 GlobeNewswire Inc

Dec 9, 2020

08:40AM EST Athenex Highlights Presentation Of Updated Phase 3 Data On Survival And Tolerability Associated With Oral Paclitaxel And Encequidar In Patients With Metastatic Breast Cancer Benzinga

08:39AM EST Athenex Presents Updated Phase 3 Data on Survival and Tolerability GlobeNewswire Inc

Dec 6, 2020

08:41AM EST Week Ahead In Biotech: FDA To Decide On Emergency Use Of Pfizer's COVID Vaccine, Hematology Conference Presentations Pick Up Pace Benzinga

Dec 2, 2020

08:00AM EST Athenex Pharmaceutical Division and Ingenus Pharmaceuticals GlobeNewswire Inc

Nov 28, 2020

01:08PM EST Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates Benzinga

Nov 17, 2020

08:09AM EST Athenex To Present Data On Oral Paclitaxel And Encequidar At 2020 San Antonio Breast Cancer Symposium Dec. 9 Benzinga

08:05AM EST -- Spotlight poster on updated PFS and OS data from the pivotal Phase 3 clinical trial of oral paclitaxel in metastatic breast cancer GlobeNewswire Inc

Nov 5, 2020

11:43AM EST Needham Maintains Buy on Athenex, Lowers Price Target to $27 Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

07:16AM EST Athenex Q3 EPS $(0.44) Misses $(0.43) Estimate, Sales $35.48M Beat $23.11M Estimate Benzinga

07:00AM EST FDA accepted and granted priority review of NDA for Oral Paclitaxel in metastatic breast cancer GlobeNewswire Inc

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 26, 2020

10:08AM EDT Benzinga's Top Upgrades, Downgrades For October 26, 2020 Benzinga

06:52AM EDT SVB Leerink Initiates Coverage On Athenex with Outperform Rating, Announces Price Target of $22 Benzinga

Oct 22, 2020

07:00AM EDT Athenex, Inc. to Report Third Quarter 2020 Earnings Results on GlobeNewswire Inc

Oct 12, 2020

04:05PM EDT Axis Therapeutics Announces Research Collaboration With PharmaEssentia For Development Of TCR-T Cell Therapy In Taiwan Benzinga

04:05PM EDT Axis Therapeutics Announces Research Collaboration with GlobeNewswire Inc

Oct 9, 2020

07:30AM EDT first-of-its-kind self-care resource for people living with metastatic breast cancer (MBC) PR Newswire

Sep 23, 2020

07:05AM EDT Athenex Announces FDA Allowance Of IND Application For TCRT-ESO-A2, A TCR-T Cell Therapy Benzinga

07:00AM EDT Athenex Announces FDA Allowance of IND Application for GlobeNewswire Inc

Sep 20, 2020

10:09AM EDT Notable Insider Buys of the Past Week: Nikola, Transdigm And More Benzinga

Sep 10, 2020

07:07AM EDT Athenex Prices 10M Share Common Stock Offering At $11/Share Benzinga

Sep 8, 2020

04:01PM EDT Athenex, Inc. Announces Proposed Public Offering of Common Stock GlobeNewswire Inc

04:01PM EDT Athenex Reports 10M Share Offering Benzinga

07:13AM EDT Quantum Leap Healthcare Collaborative and Athenex Announce the Selection of Oral Paclitaxel plus Encequidar in Combination with dostarlimab, an anti-PD-1, in the I-SPY 2 TRIAL targeting Stage 2/3 HER2+ and HER2- Breast Cancers Benzinga

07:00AM EDT Athenexs oral paclitaxel plus encequidar is being evaluated in combination with GSKs dostarlimab in the neoadjuvant chemotherapy setting GlobeNewswire Inc

Sep 1, 2020

10:06AM EDT Shares of Athenex, Inc. (ATNX) are currently gaining over 13% on Tuesday morning after the company announced that FDA accepted its NDA filing for oral paclitaxel and encequidar in metastatic breast cancer with priority review. RTTNews

07:19AM EDT Athenex Announces FDA Acceptance For Filing Of NDA For Oral Paclitaxel And Encequidar In Metastatic Breast Cancer RTTNews

07:04AM EDT Athenex Announces FDA Acceptance For Filing Of US NDA For Oral Paclitaxel And Encequidar In Metastatic Breast Cancer With Priority Review Benzinga

07:00AM EDT FDA grants Priority Review and sets PDUFA target action date of February 28, 2021 GlobeNewswire Inc

Aug 6, 2020

09:41AM EDT Athenex shares are trading higher after the company reported better-than-expected Q2 sales results. The company also raises its FY20 product sales guidance from mid-single-digit percentage growth to mid-teens percentage growth. UPDATE: Shares have since reversed. Benzinga

07:57AM EDT The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO Benzinga

07:37AM EDT Athenex Raises FY20 Product Sales Guidance From Mid-Single Digit Percentage Growth To Mid-Teens Percentage Growth Benzinga

07:36AM EDT Athenex Q2 EPS $(0.50) Misses $(0.36) Estimate, Sales $40.17M Beat $25.46M Estimate Benzinga

07:00AM EDT Regulatory progress for Oral Paclitaxel and tirbanibulin ointment is on track GlobeNewswire Inc

07:00AM EDT Athenex Announces $50 Million Revenue Interest Financing with GlobeNewswire Inc

Aug 4, 2020

09:30AM EDT Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the appointment of Robert J. Spiegel, MD, FACP, a renowned biotech and pharmaceutical executive, to its Board of Directors. GlobeNewswire Inc

Jul 27, 2020

07:00AM EDT Athenex, Inc. to Report Second Quarter 2020 Earnings Results on GlobeNewswire Inc

Share